glp-1 agonists and sglt2 inhibitors Receptor in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Perspectives in weight control in
Description
Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy
[DOI] [PubMed] [Google Scholar] 182.Hui H., Farilla L., Merkel P., Perfetti R
Companies in this space include mitochondrial uncouplers with enhanced safety profiles (Rivus, Continuum), GDF15 targeting drugs (Novo, Lilly, Janssen), anti- activin II receptor mAb (Versanis), mir-22 inhibition (Resalis Tx) and gut-brain axis modulators (Kallyope)
Diabetes (2014) 63(4):122433
